2007: SLE: Clinical Aspects and Treatment II
Search or Browse by Day

SLE: Clinical Aspects and Treatment II

1104
Testicular Sertoli Cell Function in Male Systemic Lupus Erythematosus (SLE)
1105
Prevalence and Risk Factors for Human Papillomavirus Infection and Cervical Cytological Abnormalities in Korean Patients with Systemic Lupus Erythematosus
1106
Lupus, Cervical Neoplasia and Human Papilloma Virus
1107
Estimating Age at Menopause in Patients with Systemic Lupus Erythematosus (SLE): Comparison Between Two Methods
1108
Trend of Mortality of Systemic Lupus Erythematosus (SLE) in a Southern Chinese Population between 2000 and 2006
1109
Subclinical Atherosclerosis in Chinese Patients with Systemic Lupus Erythematosus (sle): Prevalence, Risk Factors and Threshold for Screening
1110
Ethnic Differences in Patient Perceptions of Systemic Lupus Erythematosus (SLE) Disease Activity in a Multiethnic Cohort: The 1000 Canadian Faces of Lupus Study
1111
Autoantibody Prevalence in Lupus Patients and First-Degree Relatives from a Unique African American Population
1112
Physician Assessed Disease Activity Measurement or Patient Reported Lupus Flare
1113
Disease Activity, Body Image and Health Status in Lupus
1114
Predictors for Remission and Frequency of Flares in Patients with Systemic Lupus Erythematosus (SLE) of Recent Onset
1115
Disease Outcomes in the First 4 Years of SLE: Results from the SLICC Inception Cohort
1116
Accumulation of Atherosclerotic Risk Factors over 3 Years by Ethnicity in an International Inception Cohort
1117
Vitamin D Insufficiency is Prevalent in SLE patients
1118
The Characteristics of a Systemic Lupus Erythematosus (SLE) National Cohort
1119
The Influence of Cigarette Smoking on Disease Activity and Damage Accrual in SLE
1120
Patient and Clinician Perceptions of Importance Differ on Physical and Psychosocial Issues in Systemic Lupus Erythematosus (SLE)
1121
Atorvastatin Does Not Increase Bone Mineral Density in SLE Patients
1122
Effect of Mycophenolate Mofetil (MMF) on Cutaneous and Serositis Manifestations of SLE
1123
Low Mycophenolic Acid Area under the Curve is Associated with Increased SLE Activity
1124
Efficacy of Rituximab in Systemic Lupus Erythematosus: A Series of 22 Cases
1125
Relationship between Blood Hydroxychloroquine and Desethylchloroquine Concentrations and Cigarette Smoking in Treated Patients with Connective Tissue Diseases
1126
Management of Pulmonary Arterial Hypertension Associated with Systemic Lupus Erythematosus (SLE) or Mixed Connective Tissue Disease (MCTD): Immunosuppressive Therapy (IT) Alone or Combined with PAH Specific Therapies?
1127
Influence of Periodontal Disease Treatment in Systemic Lupus Erythematosus Activity
1128
The Immunosuppressive Therapy is Associated with Better Endothelial Function in SLE Patients
1129
A Novel Subset of SLE Exhibiting a Lack of Negative Feedback of Endogenous Glucocorticoid (GC); Possible Definition for GC Resistance
1130
Prospective Evaluation over Five Years of Neuropsychiatric Events in Patients with Systemic Lupus Erythematosus
1131
Time to Seizure Occurrence and Seizure Damage in a Multi-Ethnic Lupus Cohort
1132
A Difficult Diagnosis: Four Cases of Progressive Multifocal Leukoencephalopathy over Two Decades in One Rheumatological Unit
1133
Serum and Cerebrospinal Fluid (CSF) Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus (NPSLE)
1134
Impaired Implicit Learning and Memory Functions in Systemic Lupus Erythematosus
1135
Reduced C3 Binding to Streptococcus pneumoniae in Serum from Patients with Systemic Lupus Erythematosus
1136
The Presence of Anti-La Autoantibody Is Associated with a Lower Risk of Nephritis and Seizures in Lupus Patients
1137
Antibodies against the VRT101 Laminin Epitope Correlate with Human SLE Disease Activity and Can be Removed by Extracorporeal Immunoadsorption
1138
Association of the FasL-844*TT/TC Alleles with Hemolytic Anemia in Patients with Systemic Lupus Erythematosus. Results from a Multiethnic US Cohort
1139
Angiotensin-Converting Enzyme Inhibitors May Prevent Renal Involvement in Patients with Systemic Lupus Erythematosus. Results from a Multiethnic US Cohort
1140
Seizures are Important Determinants of Damage Accrual but not of Mortality in Systemic Lupus Erythematosus (SLE): Data from a Large Multiethnic Cohort
1141
High Sensitivity C-Reactive Protein (hs-CRP) is Associated with Early Damage in Systemic Lupus Erythematosus (SLE). Data from a Multiethnic Cohort
1142
Disease Activity and Alcohol Intake May Lead to Permanent Cognitive Impairment in Patients with Systemic Lupus Erythematosus (sle): Data from a Multiethnic Cohort
1143
Defining Low-Density Lipoprotein Cholesterol (ldl-c) Cut-Points For Coronary Artery Disease Risk Stratification in Systemic Lupus Erythematosus (sle)
1144
Arterial Stiffness in Active Lupus Patients with Low CAD Risk
1145
Increased Augmentation Index in Systemic Lupus Erythematosus: Relationship to Traditional Cardiovascular Risk Factors
1146
Nuclear Magnetic Resonance Spectroscopy Lipoprotein Subclasses and Particle Size in Patients with Systemic Lupus Erythematosus: Relationship with Inflammation and Coronary Atherosclerosis
1147
Premature Atherosclerosis in Young Women with SLE
1148
Serum Amyloid A and Measures of Disease Activity and Cardiovascular Risk in Patients with Systemic Erythematosus
1149
Urine Levels of sVCAM-1, but not sICAM-1 and P-Selectin, Correlate with Active Urine Sediments in SLE
1150
Prognostic Factors of Lupus Nephritis other than Renal Pathology
1151
Antiphospholipid Antibody Induced Deterioration Of Renal Function In Most Patients With Systemic Lupus Erythematosus
1152
Michigan Lupus Epidemiology & Surveillance (MILES) Program: Prevalence of Lupus Nephritis in Washtenaw County, 2002-2005
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>